Posts

Tuesday Morning Hunting Menu

Aggressive Momentum Swing Playbook – April 28, 2026 Aggressive Momentum Swing Playbook Date: April 28, 2026 Style: Aggressive Momentum / Volume Expansion / News Catalysts / 1–5 Day Swing Windows Market Context: SPX near highs, pre-FOMC chop, Big Tech earnings week, low-vol index tape but fast single-name rotations. Best setups likely come from relative volume, news continuation, and post-event directional expansion. Disclaimer: These are personal trade planning notes for structured execution and scenario mapping. Not financial advice. High-volatility momentum names—especially low-float and news-driven small caps—carry elevated risk of halts, dilution, slippage, and sharp reversals. Always verify live data, use hard stops, and size according to risk. Priority Board (What Deserves Attention First) Ticker Priority Best Entry Type Entry Zone Target Zone Retu...
Post a Comment
Read more

BSY Rebound

BSY: A Compelling Turnaround Story ZACKS STRONG BUY Bentley Systems (BSY) is currently presenting one of the most interesting turnaround setups in the software space. While the market has spent the last year repricing the stock, the underlying financials suggest a massive disconnect between price and value. $59.25 52-Week High +24% FCF Growth 2.1x Net Debt Leverage 1.04 Beta The Market Dislocation The numbers don't lie: BSY is trading approximately 64% below its 52-week high . This isn't just a routine dip; it’s a full-scale repricing. Over the past year, the stock has retreated nearly 28%, creating the kind of asymmetrical entry point that turnaround hunters thrive on. Improving Financial Health Contrary to what the stock chart might suggest, the fundamentals are actually hitting new strides. Free Cash Flow (FCF) surged to $520M in 2025 , a...
Post a Comment
Read more

NTLA Detailed Analysis

NTLA Stock Analysis — April 27, 2026 ⚠ Important Disclaimer Informational use only. I am not a financial advisor. Biotech stocks carry significant risk, including total loss. NASDAQ: NTLA CRISPR · Gene Editing Clinical Stage Intellia Therapeutics (NTLA) — Full Analysis April 27, 2026 · HAELO Phase 3 Data Day · Personal Research Note Price (intraday) $16.23 +19.1% today 52-Week Range $6.83 – $28.24 ~43% below high Market Cap ~$1.67B Small Cap Volume Today 9.0M vs 4.1M avg Section 1 — Technicals KEY PRICE LEVELS 52-wk high $28.24 Resistance R1 ~$16.25 ● Current Price $16.23 Support S1 $14.10 50-day MA $11.89 INDICATORS Indicator Signal RSI (14-day) 30–35 Oversold MACD (3-mo) Bullish ...
Post a Comment
Read more

Hi Ho Silver

Is There More “Paper Silver” Than Real Silver? What Traders Actually Need to Know April 2026 | Wild Swing Trades If you’ve spent any time around commodities traders, you’ve probably heard this claim: “There’s more silver sold on paper than physically exists.” It sounds explosive—but like most things in markets, the truth is more nuanced… and more useful for traders who know how to interpret it. The Mechanics: Paper Silver vs Physical Silver Most silver trading doesn’t involve bars being moved around. It happens through futures contracts on exchanges like COMEX (a division of CME Group). These contracts represent claims on silver—but here’s the key: the vast majority are never settled with physical delivery. Traders roll positions forward Contracts are closed before expiration Many positions offset each other (long vs short) This allows total “paper” exposure to grow far larger than the amount of physical silver sitting in vaults. So… Is There More Silve...
Post a Comment
Read more

MindMed Where Did You Go?

Did MindMed Fall Off Your Radar? 👀 Remember Mind Medicine (MindMed) Inc. — the once-hyped psychedelic biotech that had traders buzzing a few years back? If you haven’t checked in lately, you might’ve missed something big… The company has officially rebranded to Definium Therapeutics (DFTX) , and along with that shift came a noticeable change in market behavior. From Hype Cycle to “Wait… Is That Moving?” Back in the early 2020s, MindMed (MNMD) rode the wave of retail enthusiasm around psychedelics as the “next frontier” in mental health treatment. Then… it faded. Volume dropped, volatility dried up, and for many traders, it quietly slipped off the radar. But markets have short memories — and forgotten names have a habit of waking up fast. Performance Check 📈 Pull up the chart and you’ll notice something interesting: price action has started to wake up again. Whether it’s renewed interest, restructuring, or speculative rotation, DFTX is no longer completely asle...
Post a Comment
Read more

NTLA — Going Up?

Bullish Signal for NTLA: FDA Wins and Major Analyst Upgrades Overall Sentiment: Cautiously Bullish The biotech sector is often a rollercoaster, but Intellia Therapeutics (NTLA) is currently carving out a setup that demands attention. A combination of regulatory breakthroughs and shifting Wall Street sentiment suggests the stock may be at a critical turning point. 1. The Catalyst: FDA De-Risking The most significant headwind for NTLA was recently cleared. The FDA lifted the clinical hold on the late-stage MAGNITUDE Phase 3 trial . This trial focuses on an experimental gene therapy for heart disease, and moving into Phase 3 is a massive "de-risking" event. Furthermore, NTLA’s Q4 earnings report caught the market off guard. Despite forecasts predicting marginal declines, the company outperformed, sparking a notable post-earnings rally. Technical Snapshot ...
Post a Comment
Read more

EOSE What Do You See?

EOSE: Swing Setup or Falling Knife? Eos Energy Enterprises (EOSE) is flashing on scanners again. We’re seeing a classic battle between oversold technical signals and heavy fundamental headwinds. Here is the breakdown of what is moving the needle right now. View EOSE Real-Time Chart on TradingView The Bullish Case Momentum Bursts: Shares jumped 4.55% on April 22, following a massive 10.5% surge on April 15 with "directionally bullish" call volume. Oversold Signals: RSI_14 below 30 and Williams %R below -80 suggest the stock is in prime "bounce" territory. Revenue Growth: Q1 guidance ($56M–$57M) suggests record shipments despite the earnings miss. AI Narrative: A new 2 GWh partnership with Turbine-X Energy aligns EOSE with the massive energy storage demand for AI data centers. The Risk Side Trend: EOSE is down roughly 45% YTD 2026. The macro trend is still firmly bearish. ...
Post a Comment
Read more